


|  |  |                         |
|--|--|-------------------------|
|  | <b>PREMARKET NOTIFICATION<br/>SUBMISSION – 510 (k)</b> | <b>Data: 09-03-2001</b> |
|  | <b>JAMSHIDI™</b>                                       | <b>Pag. 28 di 28</b>    |

**K013070**

DEC 1 2 2001

## 510 (k) SUMMARY

- **Applicant** : **H.S. Hospital Service S.p.A.**  
Via Naro, 81 – 00040 Pomezia (Rome) Italy
- **Contact Person** : **MMC International, LLC**  
**Mr. Lucio Improta**  
**10147 Umlerland Place – Boca Raton, FL 33428**  
**Tel. (561)477-1671 - Fax. (561)477-0863**  
**e-mail : mmcintern@aol.com**
- **Submission Date** : **September 03, 2001**
- **Trade Name** : **Jamshidi Bone Marrow Biopsy Needle**
- **Common Name** : **Bone Marrow Biopsy Needle**
- **Classification Name** : **876.1075 - Biopsy instrument**

### ❖ **Indication for use :**

*This biopsy instrument is used for drawing of osteomedullary substance and or for explantation of bone marrow*



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

DEC 12 2001

H.S. Hospital Service S.p.A.  
c/o Mr. Lucio Improta  
MMC International, LLC  
10147 Umberland Place  
Boca Raton, Florida 33428

Re: K013070

Trade/Device Name: Jamshidi Bone Marrow Biopsy Needle  
Regulation Number: 876.1075  
Regulation Name: Gastroenterology-urology biopsy instrument  
Regulatory Class: II  
Product Code: FCG, KNW  
Dated: September 3, 2001  
Received: September 13, 2001

Dear Mr. Improta:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.


If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



 Celia M. Witten, Ph.D., M.D.  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

|   |  |  |
|---|--|--|
|  | <p align="center"><b>PREMARKET NOTIFICATION<br/>SUBMISSION – 510 (k)</b></p> | <p><b>Data: 09-03-2001</b></p> <p><b>Pag. 11 di 28</b></p> |
|   | <p align="center"><b>JAMSHIDI™</b></p>                                       |  |

510 (k) # **K013070**

**DEVICE NAME**

**Jamshidi Biopsy Needle**


**INDICATION FOR USE**

This biopsy instrument is used for drawing of osteomedullary substance and or for explantation of bone marrow

PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED

-----

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
 (Division Sign-Off)  
 Division of General Restorative  
 and Neurological Devices  
 510(k) Number **K013070**

Prescription Use ✓  
 (Per 21 CFR 801.109)

OR

Over-The-Counter Use \_\_\_\_\_